vs
バイオジェン（BIIB）とPrimoris Services Corp（PRIM）の財務データ比較。上の社名をクリックして会社を切り替えられます
バイオジェンの直近四半期売上が大きい（$2.5B vs $1.9B、Primoris Services Corpの約1.3倍）。バイオジェンの純利益率が高く（12.9% vs 2.8%、差は10.1%）。Primoris Services Corpの前年同期比売上増加率が高い（6.7% vs 2.0%）。バイオジェンの直近四半期フリーキャッシュフローが多い（$594.3M vs $121.1M）。過去8四半期でPrimoris Services Corpの売上複合成長率が高い（14.7% vs 0.3%）
バイオジェンは米国マサチューセッツ州ケンブリッジに本拠を置く多国籍バイオテクノロジー企業で、神経疾患の治療分野を専門としています。主力製品には多発性硬化症治療薬のテクフィデラ、脊髄性筋萎縮症治療薬のスピンラザ、フリードライヒ運動失調症治療薬のスカイクラリスなどがあり、難病・神経疾患患者向けの革新的治療法の提供に注力しています。
Primoris Services Corporationは米国に本社を置く上場の専門建設・インフラ企業で、天然ガスパイプライン、上下水道管路事業を主力としています。2014年にはフォーチュン1000にランクインしており、北米のエネルギー・生活インフラ分野で豊富な実績を有しています。
BIIB vs PRIM — 直接比較
損益計算書 — Q1 FY2026 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $2.5B | $1.9B |
| 純利益 | $319.5M | $51.7M |
| 粗利率 | — | 9.4% |
| 営業利益率 | — | 4.2% |
| 純利益率 | 12.9% | 2.8% |
| 売上前年比 | 2.0% | 6.7% |
| 純利益前年比 | 32.8% | -4.2% |
| EPS（希薄化後） | $2.15 | $0.94 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q1 26 | $2.5B | — | ||
| Q4 25 | $2.3B | $1.9B | ||
| Q3 25 | $2.5B | $2.2B | ||
| Q2 25 | $2.6B | $1.9B | ||
| Q1 25 | $2.4B | $1.6B | ||
| Q4 24 | $2.5B | $1.7B | ||
| Q3 24 | $2.5B | $1.6B | ||
| Q2 24 | $2.5B | $1.6B |
| Q1 26 | $319.5M | — | ||
| Q4 25 | $-48.9M | $51.7M | ||
| Q3 25 | $466.5M | $94.6M | ||
| Q2 25 | $634.8M | $84.3M | ||
| Q1 25 | $240.5M | $44.2M | ||
| Q4 24 | $266.7M | $54.0M | ||
| Q3 24 | $388.5M | $58.4M | ||
| Q2 24 | $583.6M | $49.5M |
| Q1 26 | — | — | ||
| Q4 25 | 78.3% | 9.4% | ||
| Q3 25 | 73.4% | 10.8% | ||
| Q2 25 | 77.1% | 12.3% | ||
| Q1 25 | 74.1% | 10.4% | ||
| Q4 24 | 76.2% | 10.6% | ||
| Q3 24 | 74.1% | 12.0% | ||
| Q2 24 | 77.8% | 11.9% |
| Q1 26 | — | — | ||
| Q4 25 | -2.5% | 4.2% | ||
| Q3 25 | 22.0% | 6.3% | ||
| Q2 25 | 28.1% | 6.7% | ||
| Q1 25 | 12.8% | 4.3% | ||
| Q4 24 | 11.9% | 5.0% | ||
| Q3 24 | 18.3% | 6.0% | ||
| Q2 24 | 28.3% | 5.5% |
| Q1 26 | 12.9% | — | ||
| Q4 25 | -2.1% | 2.8% | ||
| Q3 25 | 18.4% | 4.3% | ||
| Q2 25 | 24.0% | 4.5% | ||
| Q1 25 | 9.9% | 2.7% | ||
| Q4 24 | 10.9% | 3.1% | ||
| Q3 24 | 15.8% | 3.5% | ||
| Q2 24 | 23.7% | 3.2% |
| Q1 26 | $2.15 | — | ||
| Q4 25 | $-0.35 | $0.94 | ||
| Q3 25 | $3.17 | $1.73 | ||
| Q2 25 | $4.33 | $1.54 | ||
| Q1 25 | $1.64 | $0.81 | ||
| Q4 24 | $1.82 | $0.98 | ||
| Q3 24 | $2.66 | $1.07 | ||
| Q2 24 | $4.00 | $0.91 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $3.4B | $535.5M |
| 総負債低いほど良い | — | $469.9M |
| 株主資本純資産 | $18.7B | $1.7B |
| 総資産 | $29.5B | $4.4B |
| 負債/資本比率低いほどレバレッジが低い | — | 0.28× |
8四半期トレンド — 暦四半期で整列
| Q1 26 | $3.4B | — | ||
| Q4 25 | — | $535.5M | ||
| Q3 25 | — | $431.4M | ||
| Q2 25 | — | $390.3M | ||
| Q1 25 | — | $351.6M | ||
| Q4 24 | — | $455.8M | ||
| Q3 24 | — | $352.7M | ||
| Q2 24 | — | $207.4M |
| Q1 26 | — | — | ||
| Q4 25 | $6.3B | $469.9M | ||
| Q3 25 | $6.3B | $486.0M | ||
| Q2 25 | $6.3B | $603.1M | ||
| Q1 25 | $4.5B | $612.0M | ||
| Q4 24 | $6.3B | $734.8M | ||
| Q3 24 | $4.5B | $903.7M | ||
| Q2 24 | $6.3B | $933.0M |
| Q1 26 | $18.7B | — | ||
| Q4 25 | $18.3B | $1.7B | ||
| Q3 25 | $18.2B | $1.6B | ||
| Q2 25 | $17.6B | $1.5B | ||
| Q1 25 | $17.0B | $1.4B | ||
| Q4 24 | $16.7B | $1.4B | ||
| Q3 24 | $16.4B | $1.4B | ||
| Q2 24 | $15.9B | $1.3B |
| Q1 26 | $29.5B | — | ||
| Q4 25 | $29.4B | $4.4B | ||
| Q3 25 | $29.2B | $4.6B | ||
| Q2 25 | $28.3B | $4.5B | ||
| Q1 25 | $28.0B | $4.2B | ||
| Q4 24 | $28.0B | $4.2B | ||
| Q3 24 | $28.3B | $4.2B | ||
| Q2 24 | $26.8B | $4.0B |
| Q1 26 | — | — | ||
| Q4 25 | 0.34× | 0.28× | ||
| Q3 25 | 0.35× | 0.30× | ||
| Q2 25 | 0.36× | 0.39× | ||
| Q1 25 | 0.27× | 0.42× | ||
| Q4 24 | 0.38× | 0.52× | ||
| Q3 24 | 0.28× | 0.67× | ||
| Q2 24 | 0.40× | 0.72× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | — | $142.9M |
| フリーキャッシュフロー営業CF - 設備投資 | $594.3M | $121.1M |
| FCFマージンFCF / 売上 | 24.0% | 6.5% |
| 設備投資強度設備投資 / 売上 | — | 1.2% |
| キャッシュ転換率営業CF / 純利益 | — | 2.76× |
| 直近12ヶ月FCF直近4四半期 | $2.4B | $340.5M |
8四半期トレンド — 暦四半期で整列
| Q1 26 | — | — | ||
| Q4 25 | $511.9M | $142.9M | ||
| Q3 25 | $1.3B | $182.9M | ||
| Q2 25 | $160.9M | $78.5M | ||
| Q1 25 | $259.3M | $66.2M | ||
| Q4 24 | $760.9M | $298.3M | ||
| Q3 24 | $935.6M | $222.5M | ||
| Q2 24 | $625.8M | $16.1M |
| Q1 26 | $594.3M | — | ||
| Q4 25 | $468.0M | $121.1M | ||
| Q3 25 | $1.2B | $148.4M | ||
| Q2 25 | $134.3M | $45.3M | ||
| Q1 25 | $222.2M | $25.6M | ||
| Q4 24 | $721.6M | $270.0M | ||
| Q3 24 | $900.6M | $158.8M | ||
| Q2 24 | $592.3M | $-8.1M |
| Q1 26 | 24.0% | — | ||
| Q4 25 | 20.5% | 6.5% | ||
| Q3 25 | 48.4% | 6.8% | ||
| Q2 25 | 5.1% | 2.4% | ||
| Q1 25 | 9.1% | 1.6% | ||
| Q4 24 | 29.4% | 15.5% | ||
| Q3 24 | 36.5% | 9.6% | ||
| Q2 24 | 24.0% | -0.5% |
| Q1 26 | — | — | ||
| Q4 25 | 1.9% | 1.2% | ||
| Q3 25 | 1.8% | 1.6% | ||
| Q2 25 | 1.0% | 1.8% | ||
| Q1 25 | 1.5% | 2.5% | ||
| Q4 24 | 1.6% | 1.6% | ||
| Q3 24 | 1.4% | 3.9% | ||
| Q2 24 | 1.4% | 1.5% |
| Q1 26 | — | — | ||
| Q4 25 | — | 2.76× | ||
| Q3 25 | 2.73× | 1.93× | ||
| Q2 25 | 0.25× | 0.93× | ||
| Q1 25 | 1.08× | 1.50× | ||
| Q4 24 | 2.85× | 5.53× | ||
| Q3 24 | 2.41× | 3.81× | ||
| Q2 24 | 1.07× | 0.32× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
BIIB
| Product revenue, net | $1.8B | 71% |
| Royalty revenue on sales of OCREVUS | $317.2M | 13% |
| Contract manufacturing, royalty and other revenue | $246.9M | 10% |
| Biogen's share of pre-tax profits in the U.S. for RITUXAN, GAZYVA and LUNSUMIO | $94.7M | 4% |
| Alzheimer's collaboration Revenue | $59.5M | 2% |
| Other revenue from anti-CD20 therapeutic programs | $7.2M | 0% |
PRIM
| Energy Segment | $1.2B | 64% |
| Unit Price Contracts | $473.7M | 25% |
| Cost Reimbursable Contracts | $121.3M | 7% |
| Other | $74.9M | 4% |
